Financial Summary for Q3 Fiscal Year ending February 2026 [Japanese GAAP] (Consolidated)

Overview of Operating Results

During the cumulative third quarter period of the fiscal year ending February 2026 (March 1, 2025 to November 30, 2025), net sales amounted to JPY 1,010,394 million (6.1% YoY increase), operating income was JPY 27,562 million (20.6% YoY increase), and ordinary income reached JPY 31,413 million (19.2% YoY increase). Meanwhile, net income attributable to owners of parent for the quarter stood at JPY 12,214 million (17.3% YoY decrease), impacted by goodwill amortization expenses of JPY 5,677 million. In the merchandise segment, strengthening of point services and expansion of private brand products boosted sales, while in the pharmacy segment, an increase in stores with dispensing functions led to higher prescription volume, resulting in steady same-store sales. The total number of stores across the group was 3,003 (2,991 domestic stores).

Financial Condition and Future Outlook

Total assets reached JPY 640,895 million, an increase of JPY 60,909 million from the previous fiscal year-end, while net assets grew by JPY 7,037 million to JPY 261,523 million. Total liabilities showed an increasing trend, amounting to JPY 379,371 million. The equity ratio declined to 39.9% from 42.8% at the prior fiscal year-end. Following the management integration with Tsuruha Holdings Co., Ltd. on November 27, 2025, which resulted in delisting, the company has refrained from disclosing its full-year earnings forecast. Going forward, the company will promote its “Welcia 2.0” strategy to realize the No.1 regional health station, focusing on digital marketing and the expansion of comprehensive healthcare services.